PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Sumatriptan-induced angle-closure glaucoma: A case report.

Abstract Drug-induced bilateral angle-closure glaucoma is a rare event and should be treated correctly and promptly to prevent visual loss.
PMID
Related Publications

Topiramate induced bilateral angle-closure glaucoma.

Escitalopram-induced uveal effusions and bilateral angle closure glaucoma.

Bilateral acute angle closure glaucoma in a young patient receiving oral topiramate: case report.

Bilateral acute angle closure glaucoma following topiramate treatment.

Bilateral acute angle-closure glaucoma in a migraine patient receiving topiramate: a case report.

Authors

Mayor MeshTerms
Keywords
Journal Title medicine
Publication Year Start




PMID- 28562545
OWN - NLM
STAT- MEDLINE
DA  - 20170531
DCOM- 20170630
LR  - 20170630
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 22
DP  - 2017 Jun
TI  - Sumatriptan-induced angle-closure glaucoma: A case report.
PG  - e6953
LID - 10.1097/MD.0000000000006953 [doi]
AB  - RATIONALE: Drug-induced bilateral angle-closure glaucoma is a rare event and
      should be treated correctly and promptly to prevent visual loss. PATIENT
      CONCERNS: We report a rare case of sumatriptan-induced bilateral angle-closure
      glaucoma in a young woman with migraine, and explore the possible mechanism.
      DIAGNOSES: We describe the clinical outcome of a patient with sumatriptan-induced
      bilateral angle-closure glaucoma. The patient presented with bilateral acute
      elevation of intraocular pressure (IOP) and myopic shift. INTERVENTIONS: The
      clinical symptoms and signs resolved rapidly after treatment with a topical
      cycloplegic agent, topical steroid, and aqueous suppressant. OUTCOMES: Based on
      the suspicious of malignant glaucoma, we prescribed topical phenylephrine, whose 
      application immediately lowered the IOP. All symptoms resolved after treatment
      with a long-acting cycloplegic agent, topical steroid, and aqueous suppressant
      for 3 days. LESSONS: We presume that the mechanism underlying sumatriptan-induced
      bilateral angle-closure glaucoma may be correlated to the malignant glaucoma.
      Timely diagnosis and appropriate treatment are essential for resolving this
      ophthalmic emergency.
FAU - Hsu, Cherng-Ru
AU  - Hsu CR
AD  - Department of Ophthalmology, Tri-Service General Hospital, National Defense
      Medical Center, Taipei, Taiwan.
FAU - Chen, Yi-Hao
AU  - Chen YH
FAU - Tai, Ming-Cheng
AU  - Tai MC
FAU - Lu, Da-Wen
AU  - Lu DW
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Vasoconstrictor Agents)
RN  - 8R78F6L9VO (Sumatriptan)
SB  - AIM
SB  - IM
MH  - Adult
MH  - Diagnosis, Differential
MH  - Female
MH  - Glaucoma, Angle-Closure/*chemically induced/diagnostic imaging/drug therapy
MH  - Humans
MH  - Migraine Disorders/complications/drug therapy
MH  - Sumatriptan/*adverse effects/therapeutic use
MH  - Vasoconstrictor Agents/*adverse effects/therapeutic use
PMC - PMC5459710
EDAT- 2017/06/01 06:00
MHDA- 2017/07/01 06:00
CRDT- 2017/06/01 06:00
AID - 10.1097/MD.0000000000006953 [doi]
AID - 00005792-201706020-00021 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2017 Jun;96(22):e6953. doi: 10.1097/MD.0000000000006953.